ClinConnect ClinConnect Logo
Search / Trial NCT07116070

Sarcopenia and Related Factors in Patients With Multiple Sclerosis

Launched by SELCUK UNIVERSITY · Aug 4, 2025

Trial Information

Current as of August 19, 2025

Recruiting

Keywords

Multiple Sclerosis Sarcopenia Muscle Strength Physical Performance Nutrition

ClinConnect Summary

This clinical trial is studying how common sarcopenia—a condition that causes loss of muscle strength and mass—is in people with Multiple Sclerosis (MS). MS is a disease that affects the nervous system and can lead to problems with movement and muscle weakness. The study aims to understand how sarcopenia relates to symptoms like tiredness, disability level, nutrition, and physical activity in people with MS. Researchers want to learn more about muscle strength, body changes, and how diet and exercise might affect muscle health in this group.

People who are 18 years or older, have a confirmed diagnosis of MS, are currently stable (no recent attacks), and can still walk with some independence may be eligible to join. Participants will be asked to undergo tests that measure muscle strength, physical abilities, and body composition, as well as provide information about their nutrition and activity levels. This study hopes to find ways to detect muscle loss early and improve quality of life for people living with MS. If you meet the eligibility criteria and are interested, this study is currently recruiting participants.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Being 18 years of age or older,
  • Having been diagnosed with Multiple Sclerosis (confirmed by a neurologist),
  • Being in a stable phase of the disease (having not had an attack in the last 3 months),
  • Having preserved walking ability (EDSS score ≤6.5),
  • Being able to give informed consent to participate in the study.
  • Exclusion Criteria:
  • Having another neuromuscular disease.
  • Having developed significant muscle loss within the last 6 months due to use of corticosteroids or immunosuppressive therapy.
  • Having systemic diseases that can cause muscle loss, such as cancer, rheumatic diseases, or severe metabolic disorders.
  • Having undergone major surgery or a history of serious trauma within the last 3 months.
  • Being pregnant or breastfeeding.

About Selcuk University

Selçuk University is a prominent educational institution located in Turkey, recognized for its commitment to advancing medical research and clinical studies. As a clinical trial sponsor, Selçuk University leverages its extensive academic resources and expertise to conduct innovative research that aims to address significant healthcare challenges. The university fosters collaboration among researchers, healthcare professionals, and industry partners to facilitate the development of new therapies and improve patient outcomes. Through rigorous adherence to ethical standards and regulatory guidelines, Selçuk University strives to contribute to scientific knowledge and enhance the quality of care within the community and beyond.

Locations

Konya, Selcuklu, Turkey

Patients applied

0 patients applied

Trial Officials

İsmail ÖZSOY, Assoc. Prof. Dr.

Principal Investigator

Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Konya, Türkiye

Haluk GÜMÜŞ, Prof. Dr.

Study Chair

Selçuk University, Faculty of Medicine, Department of Neurology, Konya, Türkiye

Gülşah ÖZSOY, Assist. Prof. Dr.

Study Chair

Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Konya, Türkiye

Zehra KORKUT, Assist. Prof. Dr.

Study Chair

Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Konya, Türkiye

Yasemin GEDİKLİ, Res. Asst.

Study Chair

Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Konya, Türkiye

Emel A ATAMAN AKTAŞ, Dr.

Study Chair

Selçuk University, Faculty of Medicine, Department of Neurology, Konya, Türkiye

Omar E QUTOB, Dr.

Study Chair

Selçuk University, Faculty of Medicine, Department of Neurology, Konya, Türkiye

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported